Is Dyne Therapeutics, Inc. (DYN) a Buy, Sell, or Hold?
Dyne Therapeutics, Inc.
NASDAQ:DYN
$23.8316 USD
$0.05 (0.22%)
- Volume
- 839.48K
- Average Volume
- 1.87M
- Market Capitalization
- $3.94B
- P/E Ratio
- -7.40
- Dividend Yield
- 0.00%
- Price Target
- $35.50
- Year High
- $25.00
- Year Low
- $8.64
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $19.92
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | John G. Cox |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | DYN |
| CUSIP | 26818M108 |
| CIK | 0001818794 |
| Web | https://www.dyne-tx.com |
| Phone | 781 786 8230 |
| Currency | USD |
| Employees | 263 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 19.92 |
| Quick Ratio | 19.92 |
| Cash Ratio | 14.69 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.80 |
| Price / Cash Flow | -8.52 |
| Price / Book | 4.55 |
Price Target and Rating
| Average Stock Price Forecast | $35.50 |
| High Stock Price Forecast | $47.00 |
| Low Stock Price Forecast | $24.00 |
| Forecast Upside/Downside | -32.87% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.47 |
| Trailing P/E Ratio | -7.40 |
| PEG Ratio | -0.78 |
| P/E Growth | -0.78 |
| Net Income | $-446.21M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -58.28% |
| Return on Assets | -41.83% |
Financials Score
| AltmanZ Score | 8.76 |
| Piotroski Score | 1.00 |
| Working Capital | 969.78M |
| Total Assets | 1.08B |
| Ebit | -434.3M |
| Market Cap | 3.93B |
| Total Liabilities | 214.9M |
Poll Results
About Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts. ...
2026-07-04 09:21:09
Dyne Therapeutics is advancing a clinical-stage platform specifically targeting genetically driven neuromuscular diseases. Recursion Pharmaceuticals utilizes an artificial intelligence OS to accelerate drug discovery across several therapeutic areas.
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
2026-07-01 11:38:42
Dyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform. Vertex Pharmaceuticals maintains a dominant market share in cystic fibrosis while expanding its reach into gene editing and pain management.
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
2026-06-26 11:05:48
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.
Biotech ETF Index Surges 10% After Rebalance
2026-06-25 11:31:47
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
Dyne Therapeutics Appoints Barry Greene to Board of Directors
2026-06-22 16:10:00
WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Barry Greene to its Board of Directors. Mr. Greene brings more than three decades of biopharmaceutical industry experience and a track record of building and scaling innovative companies from development through commercialization across rare diseases, neuroscience, and oncology.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-18 16:05:00
WALTHAM, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 6 newly hired employees. The awards were made as an inducement material to the newly hired employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
2026-06-17 07:30:00
- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has entered into an amendment to its non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE: HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets.
2026-06-03 07:30:00
- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the completion of enrollment in the registrational expansion cohort (REC) of the Phase 1/2 ACHIEVE trial of zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in individuals with DM1.
Frequently Asked Questions
-
What is the current Dyne Therapeutics, Inc. (DYN) stock price?
-
Dyne Therapeutics, Inc.(NASDAQ:DYN) stock price is $23.8316 in the last trading session. During the trading session, DYN stock reached the peak price of $25 while $8.635 was the lowest point it dropped to. The percentage change in DYN stock occurred in the recent session was 0.22% while the dollar amount for the price change in DYN stock was $0.05.
-
DYN's industry and sector of operation?
-
The NASDAQ listed DYN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DYN?
-
Douglas Kerr | Chief Medical Officer
Erick J. Lucera | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer
Johanna Friedl-Naderer | Chief Commercial Officer
Oxana Beskrovnaya | Chief Innovation Officer
John G. Cox | Chief Executive Officer, President & Director -
How many employees does DYN have?
-
Number of DYN employees currently stands at 263. DYN operates from 1560 Trapelo Road, Waltham, MA 02451, US.
-
Link for DYN official website?
-
Official Website of DYN is: https://www.dyne-tx.com
-
How do I contact DYN?
-
DYN could be contacted at phone #781 786 8230 and can also be accessed through its website. DYN operates from 1560 Trapelo Road, Waltham, MA 02451, US.
-
How many shares of DYN are traded daily?
-
The average number of DYN shares traded daily for last 3 months was 1.87M.
-
What is the market cap of DYN currently?
-
The market value of DYN currently stands at $3.94B with its latest stock price at $23.8316